April 19, 2018 / 5:18 PM / 7 months ago

BRIEF-AB Science Announces Negative Opinion From CHMP

April 19 (Reuters) - AB SCIENCE SA:

* REG-AB SCIENCE ANNOUNCES THAT THE CHMP HAS ADOPTED A NEGATIVE OPINION FOR THE MARKETING AUTHORIZATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS

* AB SCIENCE WILL PROVIDE ADDITIONAL DATA THROUGH A REEXAMINATION PROCEDURE

* RE-EXAMINATION WILL LEAD CHMP TO DELIVER A SECOND OPINION IN JULY 2018

* REAFFIRMS ITS COMMITMENT TO CARRY OUT DEVELOPMENT OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below